Bova – where it all began
Bova – where it all began
Colin Bova first opened retail pharmacy doors in 1968 in the small beachside suburb of Cronulla in NSW Australia. Due to a hard work ethic and service excellence the business thrived and eventually settled in Caringbah of NSW.
2008
In 2008, Nick Bova, the youngest of Colin and Patricia’s five children and a fresh-faced pharmacy graduate, took over the family business. Inheriting the family passion for business, Nick looked outside of the box to offer something else to their loyal customers and a compounding service was introduced to the business. In addition to servicing local doctors, the business offered its service to the veterinary market.
2010
Over the next few years, countless hours were spent researching, studying and training in the fine art of compounding. The business continued to grow and, in 2010 the retail pharmacy separated. Bova Compounding emerged as one of Australia’s few stand-alone compounding facilities.
2016
By 2016 the business had grown to be the largest veterinary compounder in the country, servicing thousands of vets throughout Australia. From having only eight medications to offer in 2008, Bova Aus had since developed a formulary of over 30,000 lines, refining each formulation over the years and becoming experts in the regulatory environment surrounding the business.
2017
In 2017 Nick launched Bova UK, a Specials Manufacturer dedicated to bringing quality Specials Medications to the UK veterinary market. The Veterinary Medicines Directorate authorised the facilities with a ManSA (Manufacturer ‘Specials’ Authorisation) for sterile and non-sterile medicines. Bova UK was the first company to receive VMD authorisation to manufacture sterile products in the UK.
2022
The future The Bova Group is now part of the Nextmune family. Nextmune is a science-driven, global speciality pharmaceutical company dedicated to better health for dogs, cats and horses. Nextmune has provided Bova group with the strength, knowledge and reinforced capability to move into its next phase.
